Unethical studies of ivermectin for covid-19

BMJ. 2022 Apr 14:377:o917. doi: 10.1136/bmj.o917.

Authors

Gideon Meyerowitz-Katz¹, Sarah Wieten², María de Jesús Medina Arellano³, Gavin Yamey⁴

Affiliations

¹ School of Health and Society, University of Wollongong, Wollongong, New South Wales, Australia.
² Department of Philosophy, Durham University, Durham, England.
³ Bioethics, Health and Biolaw Program, Instituto de Investigaciones Jurídicas, Universidad Nacional Autónoma de México, Mexico City, Mexico.
⁴ Center for Policy Impact in Global Health, Duke Global Health Institute, Duke University, Durham, NC, USA gavin.yamey@duke.edu.

PMID: 35422425
DOI: 10.1136/bmj.o917

No abstract available

Publication types

Editorial

MeSH terms

Antiparasitic Agents / therapeutic use
Antiviral Agents / therapeutic use
COVID-19*
Humans
Ivermectin* / therapeutic use
SARS-CoV-2
Treatment Outcome

Substances

Antiparasitic Agents
Antiviral Agents
Ivermectin